Key result
Ximelagatran plus ASA reduced total thrombus area more than clopidogrel plus ASA under low shear rate (P<0.0001 for 72 mg) and high shear rate, with less bleeding time prolongation.
Why the study?
Does ximelagatran plus ASA reduce thrombus area more than clopidogrel plus ASA in a human ex vivo arterial thrombosis model?
Population
62 healthy male volunteers
Comparison
Ximelagatran plus steady-state acetylsalicylic… vs Clopidogrel plus steady-state ASA, and ASA alone
Design
Preclinical
Follow-up
6 days
Authors
Loading...
Animal data favor ximelagatran-ASA over clopidogrel-ASA for thrombus reduction; leaves open translation to human arterial thrombosis.
Does ximelagatran plus ASA reduce thrombus area more than clopidogrel plus ASA in a human ex vivo arterial thrombosis model?
p-value: p=<0.0001
Ximelagatran plus ASA demonstrated greater antithrombotic efficacy and less bleeding time prolongation compared to clopidogrel plus ASA in a human ex vivo thrombosis model.
Eriksson-Lepkowska et al. (2006) studied Healthy volunteers (n=62). Ximelagatran plus ASA vs. Clopidogrel plus ASA was evaluated on Changes in total thrombus area (TTA) under low shear rate (LSR) and high shear rate (HSR) conditions (p=<0.0001). Ximelagatran plus ASA reduced total thrombus area more than clopidogrel plus ASA under low shear rate (P<0.0001 for 72 mg) and high shear rate, with less bleeding time prolongation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: